Myriad Genetics, Inc. Form 10-Q Summary
Reporting period: The provided filing is for the quarter and nine months ended March 31, 2015, representing fiscal 2015 third quarter. The request metadata identifies “2014 Q3,” which does not match the filing period.
Business Context and Reporting Period
Myriad Genetics develops and commercializes molecular diagnostic tests across oncology, preventive care, rheumatology, and other disease areas. The company reported three segments: molecular diagnostics, pharmaceutical and clinical services, and research. It marketed 14 commercial tests in the United States and internationally.
- Approximately 500 U.S. sales representatives and operations in Germany and Switzerland.
- BRAC Analysis CDx received FDA approval in December 2014 as a companion diagnostic for Lynparza.
- Tumor BRACAnalysis CDx received European CE Marking in January 2015.
- The company launched a national rollout of myRisk Hereditary Cancer and introduced Myriad RBM services using the Simoa platform.
- On February 27, 2015, Myriad acquired a German clinic for $20.1 million to support market access and reimbursement negotiations in Germany.
Financial Metrics
| Metric | Three Months Ended March 31, 2015 | Three Months Ended March 31, 2014 | Nine Months Ended March 31, 2015 | Nine Months Ended March 31, 2014 |
|---|---|---|---|---|
| Total revenue | $180.0 million | $182.9 million | $533.2 million | $589.5 million |
| Operating income | $35.7 million | $55.3 million | $98.0 million | $221.2 million |
| Net income | $21.5 million | $36.8 million | $61.5 million | $142.6 million |
| Diluted EPS | $0.29 | $0.48 | $0.82 | $1.82 |
| Net cash from operations | Not separately provided | Not separately provided | $89.5 million | $149.3 million |
Margins: Gross margin was approximately 80% in both the quarter and nine-month period, compared with 85% and 87%, respectively, in the prior-year periods. Operating margin was approximately 19.9% for the quarter and 18.4% for the nine months, compared with approximately 30.2% and 37.5% in the prior-year periods. Net margin was approximately 11.9% for the quarter and 11.5% for the nine months, compared with approximately 20.1% and 24.2% previously.
Revenue mix: Molecular diagnostic testing generated $173.0 million in quarterly revenue and $516.6 million for the nine months. Pharmaceutical and clinical services generated $7.0 million and $16.6 million, respectively.
- Quarterly hereditary cancer testing revenue declined 6% to $159.0 million, while VectraDA revenue increased 236% to $10.5 million.
- Nine-month hereditary cancer testing revenue declined 14% to $474.5 million, while VectraDA revenue increased to $31.9 million from $3.1 million.
- Nine-month pharmaceutical and clinical services revenue declined 31% to $16.6 million.
Cash, Liquidity, Debt, and Capital Allocation
- Cash and cash equivalents were $55.2 million at March 31, 2015, compared with $64.8 million at June 30, 2014.
- Current and long-term marketable securities totaled $120.4 million, producing cash, cash equivalents, and marketable securities of $175.6 million versus $270.6 million at June 30, 2014.
- Net cash used in financing activities was $137.1 million, primarily reflecting $165.9 million of share repurchases.
- Capital expenditures were $21.9 million, primarily supporting expanded myRisk testing capacity.
- The board authorized an additional $200 million repurchase authorization in February 2015, increasing cumulative authorization to $1.2 billion. Approximately $199.7 million remained available at March 31, 2015.
- No senior debt or borrowings are identified in the provided balance sheet or notes. Total liabilities were $110.2 million, including $67.2 million of current liabilities and $26.1 million of unrecognized tax benefits.
- Management stated that existing capital resources and expected operating cash flow should fund current and planned operations for the next several years, subject to business and market conditions.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue decreased 2%, while nine-month revenue decreased 10%.
- Quarterly operating income declined 35% and nine-month operating income declined 56%.
- Quarterly net income declined 42% and nine-month net income declined 57%.
- Molecular diagnostic cost of revenue increased 40% for the quarter and 49% for the nine months, driven by myRisk transition costs, new tests without secured reimbursement, and VectraDA’s lower-margin mix.
- Research and development expense increased 25% for the quarter and 20% for the nine months.
- Selling, general, and administrative expense increased 4% for the quarter and 11% for the nine months, including acquisition-related costs and executive-transition share-based compensation.
- The company recorded approximately $5.2 million of accelerated share-based compensation for the CEO’s resignation agreement and approximately $3.1 million related to the former CFO’s resignation agreement.
- Share repurchases reduced weighted-average basic shares by approximately 4% year over year for the quarter and 5.5% for the nine months.
- The acquisition of the German clinic added $16.6 million of goodwill and $10.4 million of deferred grants at March 31, 2015; its purchase-price allocation remained preliminary.
Guidance, Outlook, Commentary, and Risks
- No specific revenue or earnings guidance was provided in the filing.
- Management expects research and development and selling, general, and administrative expenses to continue increasing as the company develops its pipeline, launches tests, and expands internationally.
- Management reported improved laboratory efficiencies during the quarter and expected continued improvement in myRisk turnaround times during the fourth quarter of fiscal 2015.
- Management attributed the quarterly revenue decline primarily to severe East Coast weather and the nine-month decline to myRisk transition-related turnaround times, fluctuating pharmaceutical research projects, increased competition, and the absence of the prior-year celebrity-publicity revenue benefit.
- Key risks include reimbursement uncertainty for new tests, competition, regulatory changes, intellectual-property disputes, laboratory delays, international expansion, acquisition integration, healthcare payment changes, and potential declines in testing volumes or margins.
- A New Jersey state tax examination covering fiscal years 2007 through 2013 was ongoing; the ultimate assessment could differ materially from accrued amounts.
- BRCA-related patent litigation was settled and dismissed with all remaining parties during the quarter. Management stated that it was not party to any legal proceeding expected to materially affect the business, financial position, or results of operations.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting.
Investor Verification Items
- Confirm the reporting-period discrepancy between the request metadata and the actual March 31, 2015 filing.
- Assess whether myRisk adoption, laboratory efficiency improvements, and reimbursement approvals can restore revenue growth and gross margins.
- Track hereditary cancer testing volumes, VectraDA economics, and the impact of increased competition.
- Review the remaining $199.7 million repurchase authorization against liquidity, acquisition spending, and operating cash flow.
- Verify the final purchase-price allocation and operating contribution of the German clinic.
- Monitor the New Jersey tax examination and the $26.1 million unrecognized tax-benefit balance.
- Evaluate dilution from outstanding options, RSUs, and approximately $53.1 million of unrecognized share-based compensation expense.